Amobarbital and Cardiopulmonary Bypass

The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06757868

Enrollment

Registered

2025-01-03

Start date

2025-02-01

Completion date

2026-04-30

Last updated

2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiopulmonary Bypass

Brief summary

Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Detailed description

AMO is a short acting complex I blocker that blocks mitochondrial complex I between flavoprotein and ubiquitin, and its blocking effect can be rapidly reversed. Our study is to explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.

Interventions

DRUGAmobarbital

Amobarbital 1mg/kg is given prior to cardiopulmonary bypass

DRUGMidazolam

midazolam 0.1mg/kg is given prior to cardiopulmonary bypass

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation. * ASA II-III; * surgical duration is 3-6 hours; * Sign the informed consent form

Exclusion criteria

* BMI less than 18 kg/m2 or greater than 30 kg/m2; * Individuals with a history or potential history of drug abuse or alcohol dependence; * Preoperative use of sedatives or analgesics; * Individuals with severe liver and kidney dysfunction; * Individuals who are allergic or potentially allergic to barbiturates; * Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status; * Participated in other clinical studies in the past 3 months; * The researchers believe that participants who are not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame	Description
Cardiac recurrence time	1 hour after heart beat recurrence	Stop extracorporeal circulation until heart beat time

Secondary

Measure	Time frame	Description
extubation time	1day	time from stopping anesthetics to extubation
cTnI	2 days	Using enzyme-linked immunosorbent assay (ELISA) to detect serum cardiac troponin I (cTnI) in patients

Countries

China

Contacts

STUDY_CHAIRAihua Du, Dr

Tongji Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026